CNV

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

Retrieved on: 
Mardi, mai 7, 2024
Brain, ARCHER, Complement component 1q, CNV, Research, Microglia, Incidence, Patient, Eye, Pivotal, Vasculitis, Paratriathlon, Retinal pigment epithelium, Geographic atrophy, RPE, Atrophy, Annual general meeting, Synapse, ARVO, European Medicines Agency, Overalls, Visual acuity, Medical imaging

BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today presented new analyses of ANX007 from the Phase 2 ARCHER trial in geographic atrophy (GA), and new preclinical data on the role of C1q in the pathogenic elimination of photoreceptor synapses and their protection with C1q blockade in GA. ANX007 is a first-in-class, non-pegylated antigen-binding fragment (Fab) designed to block C1q and activation of the classical complement cascade locally in the eye with an intravitreal formulation, and is the first therapeutic candidate for the treatment of GA to receive Priority Medicine (PRIME) designation by the European Medicines Agency. The data were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting.

Key Points: 
  • The data were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting.
  • “We are pleased to present additional clinical data from the ARCHER trial that are the first to show preservation of both vision and relevant anatomical structures following ANX007 treatment,” said Douglas Love, president and chief executive officer of Annexon.
  • “Importantly, the statistically significant preservation of photoreceptor anatomy measured by ellipsoid zone change highlights protection of key retinal structures associated with vision.
  • These two registrational trials are designed to confirm the Phase 2 ARCHER findings of protection against vision loss and underscore the unique neuroprotective mechanism of action of ANX007 and its competitive differentiation in visual function.

Targeted Sequencing Industry Report 2024: A $3.479 Billion Market in a Growth Phase with Illumina Dominating - Global Analysis and Forecasts 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
Vendredi, avril 19, 2024
Science, Other Science, Biotechnology, Research, Oncology, Health, Health Technology, Genetics, Breast cancer, Genomics, Ecosystem, Laboratory, CNV, Colorectal cancer, Agilent Technologies, Region, University, PerkinElmer, NGS, Automation, Single-nucleotide polymorphism, DNA, Patient, BGI Group, Data analysis, Diagnosis, Medicine, BGI, Growth, Fine chemical

The global targeted sequencing market has been characterized by intense competition, as established entities and emerging players compete for a share of the market.

Key Points: 
  • The global targeted sequencing market has been characterized by intense competition, as established entities and emerging players compete for a share of the market.
  • In 2023, North America accounted for a share of 49.90% of the global targeted sequencing market.
  • The global targeted sequencing market (by target enrichment method) was dominated by the hybridization capture segment in FY2023.
  • The global targeted sequencing market (by target capture) was dominated by the targeted DNA sequencing segment in FY2023.

Breakthrough Study Reveals Somavedic Device's Potential Impact on Wet AMD Patients

Retrieved on: 
Mardi, avril 23, 2024
AMD, Patient, CNV, Health, Angiography, Research, OCT, CRT, Quality of life, Sleep, SAN, Visual acuity

SAN FRANCISCO, April 23, 2024 /PRNewswire/ -- Somavedic, a trailblazer in sleep and digital pollution-neutralizing frequency therapy technology, in collaboration with researchers from the Eye Clinic of Jan Evangelista Purkyně University and Masaryk Hospital in Ústí nad Labem in the Czech Republic, have unveiled groundbreaking findings from a study showcasing the effectiveness of the Somavedic device in supporting individuals with wet age-related macular degeneration (wet AMD), a prevalent cause of severe vision impairment among older adults.

Key Points: 
  • The study enrolled patients with newly diagnosed wet AMD and active choroidal neovascularization (CNV), where anti-VEGF therapy was indicated.
  • Patients received a functioning Somavedic device for home use, while the other group was administered a non-functional placebo device.
  • "We are immensely encouraged by the positive outcomes of this study, which underscore the potential of Somavedic to make a meaningful impact on the lives of individuals affected by wet age-related macular degeneration.
  • The positive outcomes of this study pave the way for larger-scale clinical trials to substantiate the efficacy of Somavedic in wet AMD management.

Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases

Retrieved on: 
Mercredi, avril 10, 2024
Tsinghua University, OCTA, Alzheimer's disease, Finance, CE, Patient, Artificial intelligence, Adolescence, World's fair, Medical device regulation, Dementia, CNV, Certification, Hyperthyroidism, HK, Partnership, Policy, MICCAI, Safety, Lighting, Optical coherence tomography angiography, Intelligence, Choroidal neovascularization, Journal, Hospital, Research, Near-sightedness, Amblyopia, AI, Insurance, Strabismus, AMD, Gold medal, Diagnosis, Peking University, Conference, Growth, Biomarker, Plaque, News, Bleeding, Google Images, Rehabilitation, Medical device

Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases

Key Points: 
  • Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases
    On March 27, medical artificial intelligence company Airdoc Technology (2251.
  • In 2023, through our SaMDs and health risk assessment solutions, we serviced a total of 6.83 million cases and identified 31,459 significant positive cases.
  • In 2023, Airdoc Medical broadened its reach to include hospitals, grassroots medical institutions such as community clinics, and health examination centers.
  • In June 2023, Airdoc, in collaboration with Tsinghua University's Chang Gung Hospital, developed and validated a new deep learning-based neovascular segmentation model.

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Lundi, avril 1, 2024
Diagnosis, Civil service commission, Research, AATD, Growth, Akari, C5, Patient, Choroidal neovascularization, Sale, B4, PRV, Mortality, Hot game, Clinical trial, Therapy, Priority review, Safety, NEI, European Commission, ADC, Geographic atrophy, Hematopoietic stem cell transplantation, CNV, Pharmaceutical industry

BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights.

Key Points: 
  • BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights.
  • The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX.
  • Akari is continuing to recruit patients into the Part A portion of the Phase 3 clinical trial that has treated 10 patients to date.
  • During 2023, Akari also advanced the long-acting version of nomacopan (PASylated nomacopan) into the final stages of pre-clinical development as a treatment for geographic atrophy (GA).

Takara Bio transforms single-cell landscape with new large-scale NGS profiling system for oncology biomarker discovery

Retrieved on: 
Mardi, avril 2, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Single-cell analysis, Cell, NGS, Biomarker, RNA, ABRF, Messenger, Head, AACR, Chemistry, Neoplasm, Booth, RNA-Seq, WGA, SNV, Annual general meeting, CNV, Vaccine

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Shasta™ Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.

Key Points: 
  • Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Shasta™ Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.
  • Existing whole-genome amplification (WGA) technologies currently process 96–384 single cells per plate; the Shasta system increases WGA throughput to 1,500 cells per run.
  • In March, Takara Bio USA delivered instruments and NGS kits to early-access users, who have started producing results with the system.
  • We have two other projects in the lab where we want to do a full set of profiling of our entire model system.

BioSkryb Genomics to Present Novel Research on Tumor Heterogeneity at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Jeudi, mars 28, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Single-cell analysis, Disease, Transcriptome, Malignancy, Neoplasm, DNA, Genome, Workflow, AACR, Doctor of Philosophy, Phenotype, Genomics, SNV, Ageing, CNV, Mobile phone

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.

Key Points: 
  • BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.
  • “Tumor heterogeneity is a key challenge for researchers in the cancer research field.
  • As tumors evolve, subclones emerge with mutations that convey adaptive phenotypes, including resistance to therapies,” said Suresh Pisharody, CEO of BioSkryb.
  • “Our next generation single-cell technology gives scientists the tools to better understand the way tumors evolve with a comprehensive, scalable, and streamlined workflow.

Oxford Nanopore Technologies and SeqOne Partner to Support Interpretation of Nanopore Sequencing in Clinical Use

Retrieved on: 
Lundi, mars 11, 2024
Health Technology, Technology, Nanotechnology, Pharmaceutical, Oncology, Professional Services, Genetics, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Data Analytics, Health, Research, WGS, Nephrology, APHP, STR, Single-nucleotide polymorphism, Partnership, CFH, Patient, Chelsea Handler, RUO, HPO, Oxford Nanopore Technologies, Thrombotic microangiopathy, Developed country, Nanopore sequencing, Thrombosis, CNV, Pharmaceutical industry

Designed to streamline whole genome variant interpretation at scale, SeqOne DiagAi (RUO) saves time and reduces costs by ranking, shortlisting, and suggesting causative variants with best-in-class accuracy.

Key Points: 
  • Designed to streamline whole genome variant interpretation at scale, SeqOne DiagAi (RUO) saves time and reduces costs by ranking, shortlisting, and suggesting causative variants with best-in-class accuracy.
  • It also enables one-click HPO extraction from clinical notes with the DiagAI Notes2HPO large language model.
  • In the future, the collaboration will deliver other variant interpretation applications addressing the needs of cancer predisposition and somatic analysis.
  • “We are excited to collaborate with SeqOne to provide end-to-end solutions for our customers in rare disease and oncology.

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Retrieved on: 
Mardi, mars 5, 2024
Therapy, DLA Piper, Leukotriene B4, NEI, C5, CNV, OTC, Inflammation, Bayer, Choroidal neovascularization, ADC, Risk, AATD, American depositary receipt, Geographic atrophy, Haematopoietic system, Patient, Autoimmunity, McKinsey & Company, Hot game, LTB4, Cancer, Pharmaceutical industry

Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.

Key Points: 
  • Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.
  • An assessment of the pipeline is planned, including program prioritization, updated timelines, near-term value creation opportunities, and other considerations.
  • Key highlights of the merger include:
    The merged pipeline features a robust ADC toolkit with novel payload and linker technologies.
  • Goodwin Procter LLP is serving as legal advisor to Akari and DLA Piper LLP is serving as legal advisor to Peak Bio.

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Retrieved on: 
Mardi, mars 5, 2024
Therapy, DLA Piper, Leukotriene B4, NEI, C5, CNV, OTC, Inflammation, Bayer, Choroidal neovascularization, ADC, Risk, AATD, American depositary receipt, Geographic atrophy, Haematopoietic system, Patient, Autoimmunity, McKinsey & Company, Hot game, LTB4, Cancer, Pharmaceutical industry

Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.

Key Points: 
  • Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.
  • An assessment of the pipeline is planned, including program prioritization, updated timelines, near-term value creation opportunities, and other considerations.
  • Key highlights of the merger include:
    The merged pipeline features a robust ADC toolkit with novel payload and linker technologies.
  • Goodwin Procter LLP is serving as legal advisor to Akari and DLA Piper LLP is serving as legal advisor to Peak Bio.